Indivior Pharmaceuticals (INDV) Net Income towards Common Stockholders (2024 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Net Income towards Common Stockholders of $89.0 million for Q1 2026, up 85.42% year-over-year from $48.0 million in Q1 2025, and down 12.75% quarter-over-quarter from $102.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at $89.0 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 85.42% year-over-year to $89.0 million; the TTM figure through Mar 2026 stood at $251.0 million (up 3685.71% YoY), while the FY2025 annual figure was $210.0 million, up 2900.0% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $89.0 million, down from $102.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $102.0 million in Q4 2025, with the low at -$98.0 million in Q2 2024.
- The 3-year median for Net Income towards Common Stockholders is $42.0 million (2025), against an average of $34.0 million.
- Peak annual rise in Net Income towards Common Stockholders reached 385.71% in 2025, while the deepest fall reached 22.58% in 2025.
- Indivior Pharmaceuticals' Net Income towards Common Stockholders stood at $21.0 million in 2024, then surged by 385.71% to $102.0 million in 2025, then decreased by 12.75% to $89.0 million in 2026.
- Business Quant data shows INDV's Net Income towards Common Stockholders at $89.0 million in Q1 2026, $102.0 million in Q4 2025, and $42.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.58 Bn | 4.36 Bn | 294.00 Mn | 122.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.00 Mn |
| Mar 31, 2026 | 89.00 Mn |
| Dec 31, 2025 | 102.00 Mn |
| Sep 30, 2025 | 42.00 Mn |
| Jun 30, 2025 | 18.00 Mn |
| Mar 31, 2025 | 48.00 Mn |
| Dec 31, 2024 | 21.00 Mn |
| Sep 30, 2024 | 22.00 Mn |
| Jun 30, 2024 | -98.00 Mn |
| Mar 31, 2024 | 62.00 Mn |